Cargando…

Evaluation of microalbuminuria as a prognostic indicator after a TIA or minor stroke in an outpatient setting: the prognostic role of microalbuminuria in TIA evolution (ProMOTE) study

OBJECTIVE: Transient ischaemic attacks (TIA) and minor strokes are important risk factors for further vascular events. We explored the role of albumin creatinine ratio (ACR) in improving risk prediction after a first event. SETTING: Rapid access stroke clinics in the UK. PARTICIPANTS: 2202 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Strain, W David, Elyas, Salim, Wedge, Nicola, Mounce, Luke, Henley, William, James, Martin, Shore, Angela C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422314/
https://www.ncbi.nlm.nih.gov/pubmed/34489262
http://dx.doi.org/10.1136/bmjopen-2020-043253
_version_ 1783749260873826304
author Strain, W David
Elyas, Salim
Wedge, Nicola
Mounce, Luke
Henley, William
James, Martin
Shore, Angela C
author_facet Strain, W David
Elyas, Salim
Wedge, Nicola
Mounce, Luke
Henley, William
James, Martin
Shore, Angela C
author_sort Strain, W David
collection PubMed
description OBJECTIVE: Transient ischaemic attacks (TIA) and minor strokes are important risk factors for further vascular events. We explored the role of albumin creatinine ratio (ACR) in improving risk prediction after a first event. SETTING: Rapid access stroke clinics in the UK. PARTICIPANTS: 2202 patients attending with TIA or minor stroke diagnosed by the attending stroke physician, able to provide a urine sample to evaluate ACR using a near-patient testing device. PRIMARY AND SECONDARY OUTCOMES: Primary outcome was major adverse cardiac events (MACE: recurrent stroke, myocardial infarction or cardiovascular death) at 90 days. The key secondary outcome was to determine whether urinary ACR could contribute to a risk prediction tool for use in a clinic setting. RESULTS: 151 MACE occurred in 144 participants within 90 days. Participants with MACE had higher ACR than those without. A composite score awarding a point each for age >80 years, previous stroke/TIA and presence of microalbuminuria identified those at low risk and high risk. 90% of patients were at low risk (scoring 0 or 1). Their 90-day risk of MACE was 5.7%. Of the remaining ‘high-risk’ population (scoring 2 or 3) 12.4% experienced MACE over 90 days (p<0.001 compared with the low-risk population). The need for acute admission in the first 7 days was twofold elevated in the high-risk group compared with the low-risk group (3.23% vs 1.43%; p=0.05). These findings were validated in an independent historic sample. CONCLUSION: A risk score comprising age, previous stroke/TIA and microalbuminuria predicts future MACE while identifying those at low risk of a recurrent event. This tool shows promise in the risk stratification of patients to avoid the admission of low-risk patients.
format Online
Article
Text
id pubmed-8422314
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84223142021-09-22 Evaluation of microalbuminuria as a prognostic indicator after a TIA or minor stroke in an outpatient setting: the prognostic role of microalbuminuria in TIA evolution (ProMOTE) study Strain, W David Elyas, Salim Wedge, Nicola Mounce, Luke Henley, William James, Martin Shore, Angela C BMJ Open Medical Management OBJECTIVE: Transient ischaemic attacks (TIA) and minor strokes are important risk factors for further vascular events. We explored the role of albumin creatinine ratio (ACR) in improving risk prediction after a first event. SETTING: Rapid access stroke clinics in the UK. PARTICIPANTS: 2202 patients attending with TIA or minor stroke diagnosed by the attending stroke physician, able to provide a urine sample to evaluate ACR using a near-patient testing device. PRIMARY AND SECONDARY OUTCOMES: Primary outcome was major adverse cardiac events (MACE: recurrent stroke, myocardial infarction or cardiovascular death) at 90 days. The key secondary outcome was to determine whether urinary ACR could contribute to a risk prediction tool for use in a clinic setting. RESULTS: 151 MACE occurred in 144 participants within 90 days. Participants with MACE had higher ACR than those without. A composite score awarding a point each for age >80 years, previous stroke/TIA and presence of microalbuminuria identified those at low risk and high risk. 90% of patients were at low risk (scoring 0 or 1). Their 90-day risk of MACE was 5.7%. Of the remaining ‘high-risk’ population (scoring 2 or 3) 12.4% experienced MACE over 90 days (p<0.001 compared with the low-risk population). The need for acute admission in the first 7 days was twofold elevated in the high-risk group compared with the low-risk group (3.23% vs 1.43%; p=0.05). These findings were validated in an independent historic sample. CONCLUSION: A risk score comprising age, previous stroke/TIA and microalbuminuria predicts future MACE while identifying those at low risk of a recurrent event. This tool shows promise in the risk stratification of patients to avoid the admission of low-risk patients. BMJ Publishing Group 2021-09-06 /pmc/articles/PMC8422314/ /pubmed/34489262 http://dx.doi.org/10.1136/bmjopen-2020-043253 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Medical Management
Strain, W David
Elyas, Salim
Wedge, Nicola
Mounce, Luke
Henley, William
James, Martin
Shore, Angela C
Evaluation of microalbuminuria as a prognostic indicator after a TIA or minor stroke in an outpatient setting: the prognostic role of microalbuminuria in TIA evolution (ProMOTE) study
title Evaluation of microalbuminuria as a prognostic indicator after a TIA or minor stroke in an outpatient setting: the prognostic role of microalbuminuria in TIA evolution (ProMOTE) study
title_full Evaluation of microalbuminuria as a prognostic indicator after a TIA or minor stroke in an outpatient setting: the prognostic role of microalbuminuria in TIA evolution (ProMOTE) study
title_fullStr Evaluation of microalbuminuria as a prognostic indicator after a TIA or minor stroke in an outpatient setting: the prognostic role of microalbuminuria in TIA evolution (ProMOTE) study
title_full_unstemmed Evaluation of microalbuminuria as a prognostic indicator after a TIA or minor stroke in an outpatient setting: the prognostic role of microalbuminuria in TIA evolution (ProMOTE) study
title_short Evaluation of microalbuminuria as a prognostic indicator after a TIA or minor stroke in an outpatient setting: the prognostic role of microalbuminuria in TIA evolution (ProMOTE) study
title_sort evaluation of microalbuminuria as a prognostic indicator after a tia or minor stroke in an outpatient setting: the prognostic role of microalbuminuria in tia evolution (promote) study
topic Medical Management
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422314/
https://www.ncbi.nlm.nih.gov/pubmed/34489262
http://dx.doi.org/10.1136/bmjopen-2020-043253
work_keys_str_mv AT strainwdavid evaluationofmicroalbuminuriaasaprognosticindicatorafteratiaorminorstrokeinanoutpatientsettingtheprognosticroleofmicroalbuminuriaintiaevolutionpromotestudy
AT elyassalim evaluationofmicroalbuminuriaasaprognosticindicatorafteratiaorminorstrokeinanoutpatientsettingtheprognosticroleofmicroalbuminuriaintiaevolutionpromotestudy
AT wedgenicola evaluationofmicroalbuminuriaasaprognosticindicatorafteratiaorminorstrokeinanoutpatientsettingtheprognosticroleofmicroalbuminuriaintiaevolutionpromotestudy
AT mounceluke evaluationofmicroalbuminuriaasaprognosticindicatorafteratiaorminorstrokeinanoutpatientsettingtheprognosticroleofmicroalbuminuriaintiaevolutionpromotestudy
AT henleywilliam evaluationofmicroalbuminuriaasaprognosticindicatorafteratiaorminorstrokeinanoutpatientsettingtheprognosticroleofmicroalbuminuriaintiaevolutionpromotestudy
AT jamesmartin evaluationofmicroalbuminuriaasaprognosticindicatorafteratiaorminorstrokeinanoutpatientsettingtheprognosticroleofmicroalbuminuriaintiaevolutionpromotestudy
AT shoreangelac evaluationofmicroalbuminuriaasaprognosticindicatorafteratiaorminorstrokeinanoutpatientsettingtheprognosticroleofmicroalbuminuriaintiaevolutionpromotestudy